Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 4—April 2011

CME ACTIVITY

H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients

Christian Renaud, Alexandre A. Boudreault, Jane Kuypers, Kathryn H. Lofy, Lawrence Corey, Michael J. Boeckh, and Janet A. EnglundComments to Author 
Author affiliations: Author affiliations: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA (C. Renaud, A.A. Boudreault, L. Corey, M.J. Boeckh, J.A. Englund); Seattle Children’s Hospital, Seattle (C. Renaud, J.A. Englund); University of Washington, Seattle (J. Kuypers, L. Corey, M.J. Boeckh, J.A. Englund); Washington State Department of Health, Shoreline, Washington, USA (K.H. Lofy)

Main Article

Table 1

Demographic characteristics and underlying conditions in 8 patients with H275Y mutation of pandemic (H1N1) 2009 virus, Seattle Cancer Care Alliance, Seattle, Washington, USA, May 1, 2009–April 30, 2010*

Patient no. Age, y/sex BMI Underlying disease State of disease HCT Recent immunosuppressive therapy Concurrent illness Lymphocytes, × 103 cells/L
1†
51/M
20.5
AML
Remission
2 y post–allo-HCT
MMF, tacrolimus
GVHD, renal failure
110
2†
47/F
22.9
AML
Relapse
3 y post–allo-HCT
Chemotherapy 1 mo before influenza dx and 1 d after-dx
None
540
3
50/M
23.3
CML
Remission
9 mo post–allo-HCT
TBI, cyclophosphamide,
tacrolimus
GVHD
1,470
4
7/F
18.9
ALL
Relapse
NA
Chemotherapy 2 d after influenza diagnosis; prednisone 1.5 mg/kg/d
None
1,440
5
34/F
38.8
Hogkin lymphoma
Refractory
2 d pre–allo-HCT
TBI, fludarabine, cyclophosphamide
Renal failure
0
6†
17/M
19.5
ALL (T cell)
Remission
3 wk post–allo-HCT
TBI, fludarabine, cyclophosphamide,
MMF, CSA, prednisone 0.5 mg/kg/d
CMV, GVHD
154
7
17/M
22.4
Osteosarcoma
Relapse
NA
Chemotherapy 1 d before influenza diagnosis
Lung metastasis, thoracotomy, restrictive syndrome
366
8 8/F 14.5 Aplastic anemia Treatment NA ATG, CSA maintenance None 1,145

*BMI, body mass index; HCT, hemopoietic cell transplant; AML, acute myeloblastic leukemia; allo, allogenic; MMF, mycophenolate mofetil; GVHD, graft-versus-host disease; NA, not applicable; CML, chronic myeloblastic leukemia; TBI, total body irradiation; ALL, acute lymphoblastic leukemia; CSA, cyclosporine; CMV, cytomegalovirus; ATG, antithymocyte globuline.
†Patients previously reported in references (5,13).

Main Article

TOP